The prevalence, disease burden and prognosis of COPD in patients with cardiovascular diseases

Trial Identifier:	D2287L00041
Sponsor:	AstraZeneca
Start Date:	September 2025
Primary Completion Date:	March 2026
Study Completion Date:	June 2026
Condition:	Heart, Blood & Circulatory - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
CN	Beijing, CN, 100029
CN	Beijing, CN, 100191
CN	Shanghai, CN, 201114

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.